Trexquant Investment LP Invests $425,000 in Oric Pharmaceuticals, Inc. $ORIC

Trexquant Investment LP purchased a new position in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 76,093 shares of the company's stock, valued at approximately $425,000. Trexquant Investment LP owned about 0.11% of Oric Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ORIC. Arizona State Retirement System purchased a new position in Oric Pharmaceuticals in the 1st quarter valued at approximately $56,000. BNP Paribas Financial Markets purchased a new stake in Oric Pharmaceuticals in the fourth quarter valued at $71,000. Hsbc Holdings PLC purchased a new stake in Oric Pharmaceuticals in the first quarter valued at $102,000. Legato Capital Management LLC acquired a new position in Oric Pharmaceuticals in the first quarter valued at $109,000. Finally, Janus Henderson Group PLC acquired a new position in Oric Pharmaceuticals in the fourth quarter valued at $118,000. Institutional investors and hedge funds own 95.05% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ORIC. Zacks Research upgraded shares of Oric Pharmaceuticals to a "hold" rating in a research note on Tuesday, August 12th. Wedbush reaffirmed an "outperform" rating and issued a $20.00 price target on shares of Oric Pharmaceuticals in a report on Monday, June 23rd. Guggenheim initiated coverage on shares of Oric Pharmaceuticals in a research note on Thursday. They set a "buy" rating and a $18.00 price objective on the stock. HC Wainwright reduced their price objective on shares of Oric Pharmaceuticals from $22.00 to $19.00 and set a "buy" rating on the stock in a research note on Thursday, August 14th. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Oric Pharmaceuticals in a research report on Tuesday, July 8th. They set a "buy" rating and a $15.00 price target for the company. Eight research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Oric Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $17.29.

Oric Pharmaceuticals Stock Performance

Oric Pharmaceuticals stock opened at $10.50 on Tuesday. Oric Pharmaceuticals, Inc. has a 1 year low of $3.90 and a 1 year high of $14.67. The firm's 50-day moving average is $10.41 and its 200-day moving average is $8.11. The company has a market cap of $1.02 billion, a P/E ratio of -5.56 and a beta of 1.63.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01). As a group, sell-side analysts predict that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Insider Activity

In related news, Director Angie You bought 26,597 shares of the stock in a transaction on Friday, June 20th. The shares were purchased at an average price of $9.39 per share, with a total value of $249,745.83. Following the purchase, the director owned 26,597 shares in the company, valued at approximately $249,745.83. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Dominic Piscitelli sold 32,466 shares of the firm's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $10.50, for a total transaction of $340,893.00. Following the transaction, the chief financial officer directly owned 68,317 shares in the company, valued at approximately $717,328.50. The trade was a 32.21% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 36,776 shares of company stock worth $384,023. 5.55% of the stock is owned by corporate insiders.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.